MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
about
The Proline Cycle As a Potential Cancer Therapy Target.The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes.Amino Acid Transporters and Glutamine Metabolism in Breast Cancer.Metabolic Profiles Associated With Metformin Efficacy in Cancer
P2860
MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
@en
MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
@nl
type
label
MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
@en
MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
@nl
prefLabel
MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
@en
MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
@nl
P2093
P2860
P50
P356
P1476
MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.
@en
P2093
Christopher C Nolan
Hayley Cheung
Madeleine L Craze
Maria Diez-Rodriguez
Natasha Jewa
Nuno D M Coimbra
Rokaya El-Ansari
P2860
P2888
P356
10.1038/BJC.2017.387
P407
P577
2017-11-23T00:00:00Z